FDA expands use of the HPV vaccine to older age groups. The 9-valent vaccine for human papillomavirus (HPV), which was previously approved for children and adults ages nine through 26 years, is now approved for adults ages 27 through 45 years. The vaccine is thought to prevent cancers caused by the highest-risk strains of HPV, including cervical, vulvar, vaginal, and anal cancer in girls and women, and anal cancer and genital warts in boys and men. Having the vaccine does not eliminate the need for cervical cancer screening in women.